Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Lung Cancer

Drugs for Lung Cancer
Find financial assistance programs available for lung cancer drugs. Read More ›

Libtayo plus Chemotherapy Now FDA Approved for Advanced Lung Cancer without Genomic Alterations

Imjudo plus Imfinzi and Chemotherapy FDA Approved for Patients with Metastatic Lung Cancer

Showing Your Lungs Some Love
In her Introduction to this special issue, Lillie Shockney highlights how biomarkers influence the selection of best treatment options, the benefit of screening for lung cancer early, and how nutrition can combat unintended weight loss in patients with lung cancer. Read More ›

How Biomarkers Are Changing Lung Cancer Care
Many biologic markers (biomarkers) are known to drive cancer and its progression, allowing scientists to develop new medications to target those biomarkers and increase survival for patients with lung cancer. Read More ›

Lung Cancer Screening Could Save Your Life
When lung cancer is diagnosed at an early stage, the chance of survival is much higher than if it’s diagnosed later, which is why knowing who should be screened, and when, is crucial. Read More ›

If You Haven’t Met Your Lung Cancer Navigator Yet, Ask for an Introduction
Thoracic oncology nurse navigator Kammi Fox-Kay explores the benefits of meeting with a lung cancer navigator to ensure that you receive the best possible care available as well as important resources. Read More ›

How to Keep a Healthy Body Weight After a Lung Cancer Diagnosis

Bringing Hope to Patients with Stage IV Non–Small-Cell Lung Cancer
Dr. Sharon explains the impact of biomarker testing and targeted therapies on patients with non–small-cell lung cancer, highlighting the importance of personalized medicine in lung cancer. Read More ›

Targeted Therapies and Immunotherapies Approved for Patients with Non–Small-Cell Lung Cancer in 2020-2022
This article highlights the new therapies targeting a specific biomarker that have become available for patients with non–small-cell lung cancer in the past 3 years, significantly improving patient survival. Read More ›

Page 1 of 12